Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Breast Cancer Res Treat. 2020 Jun 19;182(3):665–677. doi: 10.1007/s10549-020-05714-2

Fig. 1-. Sequencing of plasma DNA identifies tumor-derived mutations.

Fig. 1-

DNA from plasma, tumors, and buffy coat (or normal liver sample) from 4 patients with metastatic breast cancer was used for sequencing of all exons in 149 genes. Plasma and tumor DNA sequences were compared to buffy coat or normal liver to identify somatic mutations in each patient. Mutations present in both plasma (≥5% AF) and at least one tumor specimen (≥10% AF) are indicated in heatmaps. Samples are labeled along y-axes with number of mutations found in plasma out of number of mutations called in parentheses. Mutations are indicated along x-axes. Locations of known tumors in each patient at the time of biopsy are indicated with boxes: green indicates a sequenced lesion; black indicates a non-sequenced lesion.